Navigation Links
Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5
Date:11/2/2007

GAITHERSBURG, Md., Nov. 2 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that Stanley C. Erck, the company's president and chief executive officer, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York City on Monday, Nov. 5. Mr. Erck's presentation will begin at 9:10 a.m. Eastern Time in the Kennedy I Room of the New York Palace Hotel.

Mr. Erck's presentation will focus on Iomai's portfolio of patch-based needle-free vaccines and immunostimulants, including its plans to move into Phase 3 trials for its travelers' diarrhea vaccine and the initiation of a Phase 1/2 trial of Iomai's dose-sparing adjuvant patch for use with a pandemic influenza vaccine.

To access the live audio webcast or the subsequent archived recording, log on to the Investor Relations section on the Overview page of the Iomai website at http://www.iomai.com. Please connect to Iomai's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

ABOUT IOMAI CORPORATION

Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.


'/>"/>
SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
6. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
7. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... SPRING, Md. , Dec. 2, 2016 ... new indication for Jardiance (empagliflozin) to reduce the risk ... diabetes mellitus and cardiovascular disease. "Cardiovascular ... with type 2 diabetes mellitus," said Jean-Marc Guettier ... and Endocrinology Products in FDA,s Center for Drug Evaluation ...
(Date:12/2/2016)... , December 2, 2016 ... global cardiac pacemaker market in its upcoming report titled, "Global Market Study ... a Declining CAGR of -1.4% between 2016 and 2024". The ... Mn in 2015 and this is likely to decline ... revenue, the global cardiac pacemaker market is anticipated to ...
(Date:12/2/2016)... , December 2, 2016 According to ... "Global Market Study on Automated Endoscope Reprocessors: Single Basin Automated ... of 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors ... expected to expand at a CAGR of 7.2% during an ... US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi ... be included in the 2016 “Guide to America’s Top Plastic Surgeons” for seven ... amalgamation of their education, experience, and professional associations. , One the most ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... today that it has raised $6.0 million in an initial round of funding. ... conviction that patients and their caregivers can receive far better care through the ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
(Date:11/30/2016)... Chino Hills, CA (PRWEB) , ... November 30, ... ... in eating disorder and mental health treatment has announced the opening of a ... specialized residential treatment for girls with mental health issues such as severe anxiety, ...
Breaking Medicine News(10 mins):